代谢综合征
医学
脂肪肝
胰岛素抵抗
非酒精性脂肪肝
内科学
2型糖尿病
疾病
2型糖尿病
肥胖
慢性肝病
肝硬化
胃肠病学
内分泌学
糖尿病
作者
Niki Katsiki,Pablo Pérez-Martínez,Panagiotis Anagnostis,Dimitri P. Mikhailidis,Asterios Karagiannis
出处
期刊:Current Vascular Pharmacology
[Bentham Science]
日期:2018-03-26
卷期号:16 (3): 219-227
被引量:88
标识
DOI:10.2174/1570161115666170621075619
摘要
Metabolic syndrome (MetS) is a cluster of central obesity, dyslipidaemia, insulin resistance and hypertension. MetS frequently co-exists with non-alcoholic fatty liver disease (NAFLD), which is characterized by fat accumulation in the liver in the absence of alcohol abuse, viral hepatitis and other causes of chronic liver diseases. Both MetS and NAFLD are associated with an increased risk for cardiovascular disease and type 2 diabetes mellitus. There are also other associations between MetS and NAFLD. In the present narrative review, we discuss the links between MetS and NAFLD in terms of prevalence, risk factors and treatment (both lifestyle interventions and drug therapy). Such associations highlight the common pathophysiological pathways of these metabolic disorders, although data for an independent association are not robust. Nevertheless, NAFLD may be regarded as a hepatic manifestation of MetS.
科研通智能强力驱动
Strongly Powered by AbleSci AI